Read the full article here.
This content was originally published by MarketWatch.com - Top Stories. Original publishers retain all rights. It appears here for a limited time before automated archiving. By MarketWatch.com - Top Stories
Gilead Sciences Inc.’s COVID-19 drug remdesivir will cost much less than Wall Street analysts had predicted in a move that likely points to a more measured, responsible approach to the pharmaceutical pricing of treatments and vaccines during the pandemic.